United States & IQVIA
5 shared events · Importance 3 · Last updated Aug 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: Key market for obesity drugs; pricing pressure and competition are central to the rivalry.
IQVIA: Data provider; prescription data shows oral Semaglutide demand stronger than expected.
Aug 03, 2026 · 6 articles
Business
United States: US regulators declined some China-tested drugs and called for multi-regional trials, increasing pressure on Chinese drugmakers.
IQVIA: Provided data on clinical trial concentration in China versus the US, highlighting the challenge.
Jul 15, 2026 · 6 articles
Business
United States: Cipla's North America revenue declined 21% due to loss of exclusivity on lenalidomide and quality issues with lanreotide; the company expects sequential recovery.
IQVIA: IQVIA data cited for Cipla's India business performance and market share.
Jul 23, 2026 · 6 articles
Regulatory
United States: The US is the target market for the generic Olaparib, with a $1.4B opportunity. The event reflects the US generic drug market dynamics.
IQVIA: IQVIA provided market size data cited by the company. Its role is informational.
Jul 19, 2026 · 6 articles
Business
IQVIA: IQVIA, a healthcare data analytics firm, provided data on the global pharmaceutical market's projected growth, which supports the rationale for DHL Group's investment.
Apr 05, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and IQVIA interact across events, view sentiment trends, and discover connected entities.
Open Dashboard